Showing results (81-90 of 111) with videos related to
Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancerSolange Peters, Alice T Shaw, Benjamin Besse, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 22, 2017
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)Byoung Chul Cho, Dong-Wan Kim, Alessandra Bearz, et al.Future Oncology (London, England)|November 15, 2017
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerGiulio Metro, Antonio Passaro, Giuseppe Lo Russo, et al.BJU International|June 30, 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programmeUgo De Giorgi, Giacomo Cartenì, Diana Giannarelli, et al.Clinical Lung Cancer|June 17, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural MesotheliomaGiulia Pasello, Daniela Scattolin, Eleonora Faccioli, et al.The Lancet. Oncology|June 13, 2017
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trialAlice T Shaw, Tae Min Kim, Lucio Crinò, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.La Radiologia Medica|October 13, 2019
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetingsDavide Franceschini, Alessio Bruni, Paolo Borghetti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2015
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global StudySai-Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris, et al.The Oncologist|February 20, 2024
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb TrialEmilio Bria, Floriana Morgillo, Marina Chiara Garassino, et al.Pageof 12